p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells

Cancer Research

Volumn 61, Issue 5, 2001, Pages 1957-1963

  Hirose, Y ^a   Berger, M S ^a   Pieper, R O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TEMOZOLOMIDE;

APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER CELL; CANCER GRADING; CELL CYCLE G2 PHASE; CELL DEATH; CELL FATE; DNA DAMAGE; DNA METHYLATION; DNA REPLICATION; GENE DELETION; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, ALKYLATING; BASE PAIR MISMATCH; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DACARBAZINE; G2 PHASE; GLIOBLASTOMA; HUMANS; MITOSIS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035266245     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Advances in chemotherapy for adult primary brain tumors
2. Phase I trial of temozolomide (CCR 81045: M&B 39831: NSC 362856)
3. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
4. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
5. Chemotherapy in the treatment of recurrent glioblastoma multiforme: Isofamide versus temozolomide
6. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
7. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme
8. Characterization of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity
9. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA
10. 6-alkylguanine-DNA alkyltransferase levels; studies with blasts of leukemic patients
11. 6-alkylguanine-DNA alkyltransferase activity
12. Purification and properties of O-6-methylguanine-DNA transmethylase from rat liver
13. 6-methylguanine-DNA methyltransferase expression
14. 6-methylguanine residues in E. coli DNA
15. DNA damage tolerance, mismatch repair and genomic instability
16. Involvement of the mismatch repair system in temozolomide-induced apoptosis
17. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly (ADP-ribose) polymerase
18. Treatment with temozolomide and poly (ADP-ribose) polymerase inhibitors induces early apoptosis and increase base excision repair gene transcripts in leukemic cells
19. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas
20. Microsatellite instability and PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene
21. Distribution of radiation sensitivities for human tumor cells of specific histological types: Comparison of in vitro to in vivo data
22. Clonal expansion of p53 mutant cells is associated with brain tumor progression
23. Comparative study of p53 gene and protein alterations in human astrocytic tumors
24. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies
25. A new look at the role of p53 in leukemia cell sensitivity to chemotherapy
26. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents
27. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
28. 6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells
29. A biomarker that identifies senescent human cells in culture and in aging skin in vivo
30. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
31. Telomerase activation by the E6 gene product of human papillomavirus type 16
32. Analysis of the p53 gene and its expression in human glioblastoma cells
33. Inhibition of human glioblastoma cell growth by WAF1/Cip1 can be attenuated by mutant p53
34. V143A modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status
35. Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53
36. waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs
37. Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma
38. Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents
39. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis
40. BAX expression
41. p53-independent AF1 induction by ACNU in human glioblastoma cells
42. 6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines
43. - human tumor cell lines
44. The G2 checkpoint is maintained by redundant pathways
45. p53 regulates a G2 checkpoint through cyclin B1
46. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
47. Lack of expression of tumor-suppressor genes in human malignant glioma cell lines
48. Cip1/Waf1 at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication
49. Waf1/Cip1 expression
50. Abrogation of G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells
51. (+) cells to caffeine-induced radiosensitization and override of G2 delay
52. Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation
53. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporin (UCN-01), a new G2-checkpoint inhibitor
54. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
55. The Chk1 protein kinase and the cdc25c regulatory pathways are targets of the anticancer agent UCN-01
56. The radiosensitizing agent 7-hydroxystaurosporin (UCN-01) inhibits the DNA damage checkpoint kinase hChk1